Abstract
The treatment of malignant disease in the central nervous system (CNS) by the systemic administration of monoclonal antibodies (MAbs) is fraught with difficulties. Radioimmunoconjugates penetrate the CNS poorly, and even in situations where the blood-brain barrier is disrupted, accumulation of isotope is low (Richardson et al. 1989). Isotope has been shown to accumulate more readily in necrotic, rather than viable tissue, and very little advantage of targeting can be demonstrated when the uptake of specific and irrelevant MAbs are compared. Diffusion into solid tumour deposits is limited, and repeated therapy is restricted when using murine MAbs due to the generation of a human anti-mouse antibody (HAMA) response which leads to the rapid clearance of conjugate from the body (Courteney-Luck et al. 1986).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ammirati M, Galicich JH, Arbit E, Liao Y (1987) Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21: 607–614
Bourne S, Lashford LS, Garson J, Coakham HB, Kemshead JT (1989) Monoclonal antibodies M340 and UJ181.4 recognise antigens associated with primitive neuroectodermal tumours/tissues. Hybridoma 8: 415–426
Courtenay-Luck NS, Epenetos AA, Moore R (1986) Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 46: 6489–6493
Fowler JF (1992) Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 18: 1261–1269
Fraker PJ, Speck JC (1978) Protein and cell membrane iodinations with a sparingly soluble chloride, l,3,4,6-Tetra-chloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun 80: 849–857
Harsh GR, Levin VA, Gutin PH, Seager M, Silver P, Wilson CB (1987) Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21: 615–621
ICRP (1960) Publication, no 2. Health Phys 3(1)
Lashford LS, Geraint-Davies A, Richardson RB, Bourne SP, Bullimore JA, Eckert H, Kemshead JT, Coakham HB (1988) A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumours. Cancer 61 (5): 857–868
MIRD (1971) Medical Internal Radiation Dose Committee. J Nucl Med 12: 1–32
Papanastassiou V, Pizer BL, Coakham HB, Bullimore J, Zananiri T, Kemshead JT (1993) Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer 67: 144–151
Papanastassiou V, Pizer BL, Chandler CL, Zananiri FAF, Kemshead JT, Hopkins KI (1995) Pharmacokinetics and dose estimates following intrathecal administration of 131I-MoAbs for the treatment of CNS malignancies. Int J Radiat Oncol Biol Physics 31: 541–542
Pizer BL, Papanastassiou V, Hancock J, Cassano W, Coakham HB, Kemshead JT (1991) A pilot study of monoclonal antibody targeted radiotherapy in the treatment of central nervous system leukaemia in children. Br J Haemat 77: 466–472
Richardson RB, Davies AG, Staddon GE, Jackson PC, Coakham HB, Kemshead JT (1989) Dosimetry of intrathecal 131I-monoclonal antibody in cases of neoplastic meningitis. Eur J Nucl Med 17: 42–48
Scharfen CO, Sneed PK, Wara WM, Larson DA, Phillips TL, Prados MD, Weaver KA, Malec M, Acord P, Lamborn KR, Lamb SA, Ham B, Gutin PH (1992) High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 24: 583–591
Stewart JS, Hird V, Snook D, Sullivan M, Hooker G, Courtenay-Luck N et al. (1989) Intraperitoneal radioimmunotherapy for ovarian cancer. Pharmacokinetics, toxicity and efficacy of 131I labelled MoAbs. Int J Radiat Oncol 16: 405–413
Stewart JS, Hird V, Snook D, Dhokia B, Sivolapenko G, Hooker G et al. (1990) Intraperitoneal yttrium-90 labelled MoAb in ovarian cancer. J Clin Oncol 8: 1941–1950
Walker MD, Strike TA, Sheline GE (1979) An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5: 1725–1731
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Hopkins, K., Papanastassiou, V., Kemshead, J.T. (1996). The Treatment of Patients with Recurrent Malignant Gliomas with Intratumoral Radioimmunoconjugates. In: Sautter-Bihl, ML., Bihl, H., Wannenmacher, M. (eds) Systemic Radiotherapy with Monoclonal Antibodies. Recent Results in Cancer Research, vol 141. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79952-5_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-79952-5_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79954-9
Online ISBN: 978-3-642-79952-5
eBook Packages: Springer Book Archive